The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Eurozone GDP data lifts markets as resource stocks rise

Fri, 13th Feb 2015 11:37

Stronger-than-expected Eurozone growth figures and easing concerns about Ukraine and Greece gave stocks a boost in London on Friday, with resource shares leading the advance.The FTSE 100 was trading 0.6% higher at 6,869 by midday, as metal and oil stocks tracked commodity prices higher.Eurozone gross domestic product (GDP) growth picked up to 0.3% in the fourth quarter of 2014 from 0.2% in the third quarter, surprising analysts who had expected the rate of expansion to remain unchanged.German GDP came in particularly strong, expanding by 0.7% in the fourth quarter from 0.1% the preceding three months, well ahead of the 0.3% growth predicted in Europe's largest economy.The better-than-expected data will come as welcome news for the European Central Bank president Mario Draghi, who faced an uphill task in trying to steer the Eurozone out of deflation."Mario Draghi has bought himself a bit of time, as year-on-year figures show small signs of Eurozone growth following the significant bond buying programme he announced recently," Dennis de Jong, managing director at UFX.com.Concerns about the Ukraine crisis have also eased after the country agreed to a ceasefire with Russia after tense negotiations in Minsk. However, there was continued fighting overnight in the rebel-held cities of eastern Ukraine, with the ceasefire not expected to kick in until Sunday."Investors also appear confident that a Greek disaster can also be averted on unconfirmed reports that German and Greek officials were working on a compromise in Brussels as both sides looked to soften their positions," said analyst Michael Hewson from CMC Markets. The speculation comes before the next Eurogroup meeting scheduled to begin on Monday.Anglo leads miners higherThe share price of Anglo American advanced despite the news that it has decided to write-down the value of certain assets by $3.9bn on the back of weaker iron ore prices, pushing the company into the red for the 2014 financial year. Anglo swung to a pre-tax loss of $259m in 2014, compared with a profit of $1.7bn in 2013.Other miners were also in positive territory, including BHP Billiton, Glencore and Rio Tinto, as metal prices improved. Even Fresnillo gained despite explaining how foreign exchange movements, depreciation and write-downs would adversely affect its 2014 results.Oil stocks such as Tullow, BG and Premier Oil were also in demand was Brent crude continued its rebound and was trading above $60 a a barrel for the first time in 2015.Glaxosmithkline's shares were given a boost by UBS which upgraded its rating for the pharmaceutical stock by two notches from 'sell' to 'buy', saying that the business is now at an "inflection point" after a tough few years. The bank hiked its target price for the stock from 1,250p to 1,700p,Utilities group Severn Trent declined after saying that while it is on track to hit expectations this financial year, operating costs are expected to rise due to the impact of inflation and quasi taxes.Rolls-Royce also fell despite the engine maker meeting forecasts with its 2014 results, as it said it expects profits to fall further this year as customers face "increased uncertainty" from weaker oil prices.Shire edged higher after a strong jump the previous session following its fourth-quarter results. The pharma group was also in focus on speculation it is preparing to make a bid for US peer Salix Pharmaceuticals, worth $9.2bn at current market prices.Market MoverstechMARK 3,126.19 +0.32%FTSE 100 6,869.16 +0.60%FTSE 250 16,894.80 +0.51%FTSE 100 - RisersTullow Oil (TLW) 403.20p +4.70%Glencore (GLEN) 288.30p +4.12%BHP Billiton (BLT) 1,554.00p +3.98%GlaxoSmithKline (GSK) 1,544.50p +3.97%Anglo American (AAL) 1,206.50p +3.52%Rio Tinto (RIO) 3,139.00p +3.27%Antofagasta (ANTO) 728.50p +3.26%BG Group (BG.) 962.80p +3.04%Weir Group (WEIR) 1,889.00p +2.66%Barclays (BARC) 258.75p +2.13%FTSE 100 - FallersBT Group (BT.A) 440.10p -2.20%United Utilities Group (UU.) 954.00p -1.95%easyJet (EZJ) 1,708.00p -1.95%InterContinental Hotels Group (IHG) 2,623.00p -1.58%SSE (SSE) 1,577.00p -1.44%ARM Holdings (ARM) 1,070.00p -1.38%Ashtead Group (AHT) 1,086.00p -1.27%National Grid (NG.) 883.50p -1.24%Severn Trent (SVT) 2,033.00p -1.17%Sage Group (SGE) 469.70p -1.05%FTSE 250 - RisersAfren (AFR) 8.26p +16.17%Vedanta Resources (VED) 523.50p +10.68%Premier Oil (PMO) 167.70p +5.54%RPS Group (RPS) 239.20p +5.42%Kaz Minerals (KAZ) 256.80p +4.26%Evraz (EVR) 194.30p +3.74%BlackRock World Mining Trust (BRWM) 331.60p +3.46%Atkins (WS) (ATK) 1,355.00p +3.04%Lonmin (LMI) 161.60p +2.93%Oxford Instruments (OXIG) 735.50p +2.87%FTSE 250 - FallersAO World (AO.) 285.90p -6.14%Supergroup (SGP) 1,022.00p -3.49%Bwin.party Digital Entertainment (BPTY) 99.05p -3.37%Acacia Mining (ACA) 273.40p -2.74%Hunting (HTG) 494.10p -1.77%Ocado Group (OCDO) 385.00p -1.53%Euromoney Institutional Investor (ERM) 985.00p -1.50%Go-Ahead Group (GOG) 2,422.00p -1.30%Rank Group (RNK) 184.70p -1.23%TalkTalk Telecom Group (TALK) 319.90p -1.17%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.